Telo Genomics to present abstract at myeloma meeting

Executive Summary

• Telo Genomics Corp. announced that its abstract regarding "3-D Telomere Profiling of MRD (Minimal Residual Disease) in Liquid Biopsy" has been accepted for a poster presentation at the 22nd International Myeloma Society annual meeting in Toronto, Canada (Sept. 17-20, 2025).
• The company disclosed the issuance of 411,539 common shares to Trusted Health Advisors LLC (THA) to compensate for partnering and commercialization services provided from January to July 1, 2025.
• The share issuance was valued at approximately $50,369 (CAD), with specific pricing tiers and voluntary resale restrictions attached to the shares.

Key Details

• Conference Acceptance:
  • Event: 22nd International Myelium Society Annual Meeting.
  • Location: Toronto, Canada.
  • Dates: September 17 to September 20, 2025.
  • Presentation Title: "3-D Telomere Profiling of MRD (Minimal Residual Disease) in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression."
  • Presenter: Dr. Yulia Shifrin, Laboratory Director of Telo Genomics.
  • Publication: Abstract will be published in Clinical Lymphoma, Myeloma & Leukemia.
  • Technology: Utilizes TeloView profiling methodology for MRD assessment.
• Share Issuance to Trusted Health Advisors LLC (THA):
  • Total Shares Issued: 411,539 common shares.
  • Purpose: Compensation for partnering and commercialization services provided from January to July 1, 2025.
  • Tranche 1: 214,605 shares issued at a deemed price of $0.12 per share.
  • Tranche 2: 196,934 shares issued at a deemed price of $0.125 per share.
  • Total Consideration: Approximately $50,369 (CAD) / $36,000 (USD).
  • Hold Period: All shares subject to a four-month hold period expiring November 11, 2025.
  • Voluntary Resale Restrictions:
    • Shares issued at $0.12/share: Restriction expires March 31, 2026.
    • Shares issued at $0.125/share: Restriction expires June 30, 2026.
• Market Context (MRD):
  • MRD (Minimal Residual Disease) is defined as small numbers of cancer cells remaining after treatment.
  • FDA Oncologic Drugs Advisory Committee voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies.
  • Global MRD testing market size expected to reach $4.1 billion (USD) by 2032.
• Company Background:
  • Telo Genomics is developing the Telo-MM application for multiple myeloma.
  • Technology backed by 160+ peer-reviewed publications and 30+ clinical studies involving 3,000+ patients.

Notable Quotes

• "We are excited to share the next clinical application of our 3-D telomere application for MRD for multiple myeloma at IMS," said Dr. Sabine Mai, Telo's co-founder. "The acceptance is a result of our commitment to develop a clinical offering and a novel approach of liquid biopsy MRD."